{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of confidence interval was not estimable due to small number of patients with events.","groupId":"OG000","lowerLimit":"11.8","upperLimit":"NA","value":"27.7"},{"comment":"Median OS for Phase 1, Dose Level 0b and upper limit of confidence interval were not estimable due to small number of patients with events.","groupId":"OG001","lowerLimit":"4.2","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of confidence interval was not estimable due to small number of patients with events.","groupId":"OG002","lowerLimit":"4.0","upperLimit":"NA","value":"12.8"},{"comment":"Upper limit of confidence interval was not estimable due to small number of patients with events.","groupId":"OG003","lowerLimit":"11.6","upperLimit":"NA","value":"17.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"40"}],"units":"Participants"}],"description":"After completion of treatment, all subjects are followed for survival every 3 months for up to 3 years following initiation of study treatment or or for subjects continuing treatment, completion of study treatment whichever was longer. OS is measured from the date of the first dose of study treatment to the date of death or last follow-up. Subjects lost to follow-up are censored on the date when they were last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects received PLD (40 mg/m\\^2 IV on Day 1 of every cycle) + durvalumab (3 mg/kg Q2W \\[equivalent to 450 mg Q4W\\] IV on Days 3 and 17 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m\\^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Days 3 and 17 of Cycles 4-12.","id":"OG000","title":"Phase 1, Dose Level 0a"},{"description":"Subjects received PLD (40 mg/m\\^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.0 mg/m\\^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.","id":"OG001","title":"Phase 1, Dose Level 0b"},{"description":"Subjects received PLD (40 mg/m\\^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m\\^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.","id":"OG002","title":"Phase 1, Dose Level +1"},{"description":"Subjects received the MTD determined in Phase 1, comprising PLD (40 mg/m\\^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment.","id":"OG003","title":"Phase 2"}],"paramType":"MEDIAN","populationDescription":"The population comprises all subjects who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to 36.6 months","title":"Median Overall Survival (OS) as Estimated Using the Kaplan-Meier Method","type":"SECONDARY","unitOfMeasure":"months"}